peeyam
- 08 May 2007 11:30
LONDON (AFX) - Provexis PLC said it has entered into a long-term collaboration agreement with Unilever PLC to jointly develop a new concentrated format of its patented Fruitflow heart-health technology for application in Unilever's food product portfolio.
Financial details of the deal were not disclosed.
The partners plan to enter into a global licence arrangement for the technology.
Fruitflow is a patented natural extract from tomato which Provexis said has been shown in human trials to reduce the propensity for aberrant blood clotting that is typically associated with cardiovascular disease and which can lead to heart attack or stroke.
In 2005 the market for heart benefit foods was worth 4 bln usd globally, Provexis added.
Considering the growth potential this share has a target of about 8-10p in the medium tern and is a good buy at current levels
As usual, pls do ur own research.
Global Nomad
- 23 Sep 2009 07:59
- 553 of 1204
RF, seems you have made your mind up which is fine, others have followed up my post with somne details and noted that there is no point in posting the whole research that makes us believe in this company.
The fact that you think we are talking about aspirin use for headaches says it all.
I agree with your caution (which is valid) but unfortunately it is not based on the full picture. You talk about being into oil and we see all the valuations based on (gu)estimates of the amount of barrels of oil in the ground and then you say that you are suspect of the valuation of this product. We are looking at potential rather than actual income currently and their is, as always, a risk of the whole thing underperforming - I have been in this for 4 years or so and spent long enough at a loss and in the doldrums at 1p whilst all the potential was building up and it has now broken free.
You need to make your own decisions/judgements and thats important. Keep us on the ground, if you can.
cynic
- 23 Sep 2009 08:05
- 554 of 1204
first of all, many thanks to you all for enlightening me a little, though i still do not understand why this long drawn-out nonsense about wording - wording of what exactly???
anyway, i have an even more jaundiced view of snakeoil manufacturers than onfmost others, and with good reason - few of them last the course and even SHP, which i have followed for a long time and is very successful, has had a pretty volatile ride.
had i known about PXS 2 years ago, i might well have been suckered by the seemingly imminent golden future and been walloped accordingly.
today, things are apparently greatly different, but the question to be asked apart from the obvious, is whether or not the company is truly worth its 100m valuation today, and that is not at all obvious.
the only thing that keeps me in, way beyond my initial and then subsequent target, is that sp continues to rise (again this morning) with very high volumes, but common sense - which may or may not prevail - dictates that at least partial profits should now be taken or even have been taken.
required field
- 23 Sep 2009 08:16
- 555 of 1204
It's up again !....probably just on volume and potential....I just can't see what the market seems to be seeing.
blanche
- 23 Sep 2009 08:18
- 556 of 1204
This product is scientifically proven, and now efsa have approved this. We are now only waiting on the EC to approve wording for the product in laymans wording. For example Danones yogurt says improves digestive tract. If they put on the side of what ever packet, the full scientific wording, joe public wouldnt understand it. Once this is approved then i feel that deals are already in place and this will fly. imvho
blanche
- 23 Sep 2009 08:20
- 557 of 1204
2.3 million traded in the first twenty minutes
cynic
- 23 Sep 2009 08:27
- 558 of 1204
SEO has a proven product too; it's just that no one will buy it and/or SEO can't actually produce it commercially!
required field
- 23 Sep 2009 08:32
- 559 of 1204
market cap 100 million and rising...incredible...
blanche
- 23 Sep 2009 08:32
- 560 of 1204
From Foodeagle on iii
I am still waiting for the final EU wide approval of the claim by the EU Commission ("wording") on fruitflow (@ guys, EFSA has done its job, it is now up to the EU Commission to do its legal act: the approval of a consumer understandable wording). This would reasonable open the entire EU market for PXS (and its future partners), a huge market from which 90 % of the functional food industry will have to leave in 2010 because their claims have not been scientifically confirmed by EFSA.
I must admit, it is much nicer to wait for the next steps ("Wording", & "transformational steps") when PXS SP is double digits and rising than at 5-6 p and falling.
Some traders left 15+ (congrats, at least so far), many others left with losses in panic at less than 10p. That's what I have meant, that the market (and its volatility) will kick out most of those who did not a proper research on PXS, and on the regulatory framework. I am sure that this extreme volatility and the sharp drop once intraday towards 4 pc after the high, resulted that now the shares are in stronger hands than they had been before> good for the SP. The opportunities are extremely significant IF the fruitflow versus Asprin trial reveals results showing that fruitflow is as effective as Aspirin (but with less or no side effects).
However, my short-medium expectations (until end of this years) have been alsways been based on the "wording", the following deals with majors and the media coverage will be very supportive for the PXS SP towards the end of this year, less on the trial. It is almost impossible to predict any price, but if the next steps come as I expected, I would say PXS should easily make new all time highs, maybe 25-30 p by end this year.
I am not a good trader, and my holdings are too large for this stock to trade, so I "do not have" another choice than just to wait and see, if my assumptions were right and re-evaluate when something significant happens. So basically, nothing new what I could tell you.
From the SP and the volumen, it seems to me that something happened on Friday late morning, which seems to responsible for the recent ride (?) at least that's my feeling.
Global Nomad
- 23 Sep 2009 08:35
- 561 of 1204
ok, lets have another go.
New regulations in the EU mean that all food products that make any claim for their benefits/effects need to be scientifically substantiated and subsequently approved by the European Commission. This is for both the science which is checked by EFSA (european food standards agency) and the consumer orientated wording that can be used on packaging/marketing that communicates this efficacy. This rules are due to come into force in Jan 2010 though there is a transition period.
To date the only product that has been scientifically approved through this process is Provexis' Fruitflow. Major multinationals have not had their claims approved including the likes of Danone - all that bioyogourt hasn't been shown to match the claims ( danone actually withdrew its application). Any producer who does not have approval will have to withdraw their product or remove science/health claims on its packaging. Many companies will be after continuing to exploit the growing functional food market by adding fruitflow to their ranges.
Coca Cola and Unilever have had exclusive agreements to develop with Provexis for the past two years versions of the product that can be used in drinks spreads etc.
The science has been approved and we are waiting for the approved consumer friendly wording which is currently being negotiated. The expectation is that following this the news will also come of commercial product agreeements leading to revenue.
On top of this are the trial results for anti thrombotic and stroke prevention effects in comparison with aspirin - taken daily by millions of people(esp in usa) - aspirin having some serious side effects in many people if taken regularly for extended periods.
The company also has other research ongoing.
the wording will allow final assessment of how marketable and consumer friendly the packaging can be - not too much science that people get confused but enough for them to know it really does do what is claimed.
blanche
- 23 Sep 2009 08:38
- 562 of 1204
Agreed with you cynic re- seo. But pxs obviously can produce the product at a commercial price, as they already have fruitflow in sirco selling rapidly on the shelves. Plus if it wasnt viable then these host of major companies would have dropped the product by now. aimvho gl
Global Nomad
- 23 Sep 2009 08:40
- 563 of 1204
RF - do you hold shares still ? hope so.
PS fruitflow is on sale in Sirco juice already and whilst not tearing up the market it has proven the commercialisationability(?*!) of the product
blanche
- 23 Sep 2009 08:40
- 564 of 1204
Looks like even bigger volumes today 5 mill now in 40 mins.
blanche
- 23 Sep 2009 08:41
- 565 of 1204
GN you what! lol
cynic
- 23 Sep 2009 08:44
- 566 of 1204
trial results for anti thrombotic and stroke prevention effects in comparison with aspirin - presumably is still "work in progress", so if those come out as unproven or similar, then presumably sp will plummet.
required field
- 23 Sep 2009 08:50
- 567 of 1204
No, not in but I have twice made a small profit...looking at the sp : should have stayed put...it's just that competing with aspirin....?...there will be years of tests and at what price on the market ?.....the beat thing with this stock is to trade it up and down and forget about what it does ! or does not.
Global Nomad
- 23 Sep 2009 08:54
- 568 of 1204
earlier trials showed the effects were there - so unproven is not on the agenda - this larger trial is a comparitive study, published results are expected shortly. They are not showing if it works but how it works at in comparison to aspirin. ie effects and side effects. Even if it works less effectively ( very unlikely) it has no demonstrated side effects so would be a safer option - aspirin can cause gastric bleeding and ulcers amongst other side effects but people take that risk to avoid more serious conditions! It may even mean it can be sold at at higher price if it is a superior product.
required field
- 23 Sep 2009 08:57
- 569 of 1204
Guys....I know I'm not in but on this new peak ; take at least 25% profits...it's still very risky.
cynic
- 23 Sep 2009 09:00
- 570 of 1204
thanks GN .... i already knew about the side effects of aspirin .....
surely if it is a "comparative study", by implication it is to show (or otherwise) that fruitflow is at least as effective as aspirin and without the side-effects - i.e. the earlier trial only indicated that it might (well) be
the how and why fruitflow works, if that is indeed the case, is surely more of scientific interest than relevance to the layman.
Global Nomad
- 23 Sep 2009 09:07
- 571 of 1204
even the layman has some need to know that what he is taking has been tested and proven especially when it comes to health. The layman should have more than a passing interest in science but maybe that's too hopeful!
cynic
- 23 Sep 2009 09:12
- 572 of 1204
yes and no ..... layman only wants to know that is has been shown to work and to do so safely; the why and how or even interest in same, is far beyond the mental capacity of the Great Unwashed